Project Grant R01AR085933
Award Date 9/15/25
Completion Date 6/30/29
Dollars Obligated $346K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $228,218 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct the "SGLT2I AS NOVEL GOUT CARE (SAVE-CARE): A RANDOMIZED CONTROLLED TRIAL". The project aims to evaluate the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a novel...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $240,715.00 to the University of Alabama at Birmingham (UAB) to explore the burden of gout in patients with chronic kidney disease (CKD) transitioning to end-stage kidney disease (ESKD) and kidney transplantation (KT). The research aims to use data from the United States Renal Data...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $176,040 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to fund a 5-year study titled "Understanding Glucocorticoid Toxicity: The Impact of Glucocorticoid Regimens on Toxicities, Clinical Outcomes, and Quality-of-Life in Vasculitis." The principal investigator, Dr. Naomi J. Patel, is an Instructor in Medicine at Harvard Medical School...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $298,915 to Cyrus Biotechnology, Inc. to develop advanced uricase enzyme variants for improved treatment of gout. The key objectives are to engineer uricase proteins with enhanced stability, reduced immunogenicity, and extended half-life, which can address the limitations of current...
- This federal Project Grant award of $777,869 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a randomized, double-blind, controlled, multi-center clinical trial to investigate the use of colchicine in treating Calcium Pyrophosphate Deposition Disease (CPPD), a prevalent but underserved form of inflammatory arthritis. The goal is to better understand colchicine's impact on the NLRP3 inflammasome and downstream pathways, which play a key role in CPPD...
- This Project Grant award, valued at $359,133.00, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports the generation of new genetic tools to enable more targeted and specific analysis of tendon and musculoskeletal tissues in mice. The goal is to develop constitutive and inducible FLP alleles that can be used in combination with existing...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $249,218 Project Grant to Yale University to validate quantitative outcomes for measuring changes in systemic sclerosis (SSc)-associated calcinosis cutis over a 6-month period. The grant, under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, will support the evaluation of the Mawdsley Calcinosis Questionnaire and a quantitative CT imaging outcome to assess changes in painful...
- The federal Project Grant award of $426,889.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the molecular regulatory mechanisms of a cartilage-enriched G-protein coupled receptor (GPCR) named ADGRG6 and its role in maintaining joint and cartilage homeostasis. The project, awarded to the University of Southern California, aims to investigate the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $331,051 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Tufts Medical Center Parent, Inc. The award will fund a 3-year study examining the use of Veverimer, a non-absorbable polymer, to decrease net acid excretion and bone resorption in adults with osteopenia. The study aims to evaluate Veverimer as a novel treatment to reverse the adverse effects of...